BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30050321)

  • 1. Differential diagnostic value of
    He X; Zhao L; Guo X; Zhao L; Wu J; Huang J; Sun L; Xie C; Chen H
    Cancer Manag Res; 2018; 10():2105-2115. PubMed ID: 30050321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of MR imaging and FDG-PET/CT in the differential diagnosis of benign and malignant vertebral compression fractures.
    Cho WI; Chang UK
    J Neurosurg Spine; 2011 Feb; 14(2):177-83. PubMed ID: 21214309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation between malignant and benign pathologic fractures with F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.
    Shin DS; Shon OJ; Byun SJ; Choi JH; Chun KA; Cho IH
    Skeletal Radiol; 2008 May; 37(5):415-21. PubMed ID: 18309481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of
    Zheng F; Wanjun X; Shuaishuai W; Tong W; Lue Z
    Med Int (Lond); 2021; 1(5):23. PubMed ID: 36698530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of
    Ma G; Zhang X; Wang M; Xu X; Xu B; Guan Z
    Quant Imaging Med Surg; 2021 May; 11(5):2013-2018. PubMed ID: 33936982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic contrast-enhanced MRI versus
    Feng F; Qiang F; Shen A; Shi D; Fu A; Li H; Zhang M; Xia G; Cao P
    Chin J Cancer Res; 2018 Feb; 30(1):21-30. PubMed ID: 29545716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic accuracy of (18)F-FDG PET/CT compared with that of contrast-enhanced MRI of the breast at 3 T.
    Magometschnigg HF; Baltzer PA; Fueger B; Helbich TH; Karanikas G; Dubsky P; Rudas M; Weber M; Pinker K
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1656-1665. PubMed ID: 26121928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
    Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
    Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation and diagnosis of benign and malignant testicular lesions using 18F-FDG PET/CT.
    Shao D; Gao Q; Tian XW; Wang SY; Liang CH; Wang SX
    Eur J Radiol; 2017 Aug; 93():114-120. PubMed ID: 28668404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of prebiopsy FDG-PET/CT in discriminating malignant from benign vertebral bone lesions in a predominantly oncologic population.
    Loudini N; Glaudemans AWJM; Jutte PC; Yakar D; Kwee TC
    Skeletal Radiol; 2020 Sep; 49(9):1387-1395. PubMed ID: 32253470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indirect comparison of the diagnostic performance of
    Hu X; Li D; Liang Z; Liao Y; Yang L; Wang R; Wang P; Cai J
    BMC Cancer; 2021 Oct; 21(1):1080. PubMed ID: 34615498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual time point [18F]Flurodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT) with water gastric distension in differentiation between malignant and benign gastric lesions.
    Farghaly H; Alshareef M; Alqarni A; Sayed M; Nasr H
    Eur J Radiol Open; 2020; 7():100268. PubMed ID: 32964074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in sublingual and submandibular salivary gland tumors.
    Ma S; Liu Y
    Mol Clin Oncol; 2020 Oct; 13(4):27. PubMed ID: 32765874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions?
    Kunikowska J; Matyskiel R; Toutounchi S; Grabowska-Derlatka L; Koperski L; Królicki L
    Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2273-80. PubMed ID: 25027709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous whole body (18)F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging for evaluation of pediatric cancer: Preliminary experience and comparison with (18)F-fluorodeoxyglucose positron emission tomography computed tomography.
    Pugmire BS; Guimaraes AR; Lim R; Friedmann AM; Huang M; Ebb D; Weinstein H; Catalano OA; Mahmood U; Catana C; Gee MS
    World J Radiol; 2016 Mar; 8(3):322-30. PubMed ID: 27028112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
    Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
    Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of
    Wang X; Zhou D; Kong Y; Cheng N; Gao M; Zhang G; Ma J; Chen Y; Ge S
    EJNMMI Res; 2023 Oct; 13(1):89. PubMed ID: 37819414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.